Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
XENETIC BIOSCIENCES INC (XBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.86-7.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for XBIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
reduce net loss per share to less than -$0.5 | Analysts expect losses to shrink from -$3.32 to -$0.34 per share by next year. | Intact | mean EPS remains below -0.5 USD per share in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology business, not a proven durable compounder. The long-term thesis is in a watch state: management is advancing its DNase oncology platform and strategic alternatives, but recent financial performance remains weak and risk is high.
The evidence describes XBIO as cheap versus peers, while the model has low confidence and the expectations gap is negative. Pricing is tagged as justified, with no fragility gates triggered, so the evidence does not point to clear signs of excessive expectations or a fragile valuation setup.
Near term, royalty revenue has provided recurring funding, though it remained modest and moved from about $0.8 million in 2026-Q1 to $0.7 million in 2026-Q2. Management is on track with advancing the DNase platform and maintaining financial discipline, while execution of strategic alternatives is mixed despite the definitive share exchange agreement with Santersus AG. Weak recent performance and a higher-than-average risk of missing the next print remain important concerns.
Over the next one to three years, the thesis hinges on progress toward clinical development of the DNase platform, continued royalty funding, and the outcome of the Santersus agreement. Near term, a weakening jobs report could deepen recession concerns, while continued strong results from Healthcare bellwethers could sustain sector support; misses or lower guidance from those companies could weaken that tailwind.
XBIO’s long-term thesis has some execution progress and sector support, but it remains a high-risk, loss-making story with weak recent performance and uncertain strategic execution. The next phase depends on platform progress, recurring royalties, and the Santersus transaction. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in XENETIC BIOSCIENCES INC's published investment case. The stated target is revenue >= 1.5 million USD. |
| Intact |
| revenue remains below 1.5 million USD in FY27 |
Revenue: $660,601 FY2026-Q2; GAAP. Published target: revenue >= 1.5 million USD. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026660,601 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
stock price stays below $20 to reflect risk | A supporting condition in XENETIC BIOSCIENCES INC's published investment case. The stated target is stock price <= 20 USD. | Under Pressure | stock price rises above 20 USD without profit progress | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.34 → $-0.34 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-07-25 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-07-26 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-07-27 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-07-28 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-07-29 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-07-30 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-07-31 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-08-01 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-02 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-03 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-08-04 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-08-05 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-06 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-08-08 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-09 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-10 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-12 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-08-13 | $-0.34 | $1,902,000 | 1 / 1 |
| 2026-08-14 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-15 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-16 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-17 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-18 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-19 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-20 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-21 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-22 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-23 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-24 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-25 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-26 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-27 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-28 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-29 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-30 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-08-31 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-01 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-02 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-03 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-04 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-05 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-06 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-07 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-08 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-09 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-10 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-11 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-12 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-13 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-14 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-15 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-16 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-17 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-18 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-19 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-20 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-21 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-22 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-23 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-24 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-25 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-26 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-27 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-28 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-29 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-09-30 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-01 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-02 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-03 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-04 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-05 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-06 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-07 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-08 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-09 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-10 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-11 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-12 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-13 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-14 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-15 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-16 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-17 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-18 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-19 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-20 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-21 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-22 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-23 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-24 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-25 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-26 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-27 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-28 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-29 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-30 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-10-31 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-11-01 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-11-02 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-11-03 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-11-04 | $-0.34 | $2,500,000 | 1 / 1 |
| 2026-11-05 | $-0.34 | $2,500,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.